Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Q32 Bio (NASDAQ:QTTB – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Valuation & Earnings

This table compares Dianthus Therapeutics and Q32 Bio”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dianthus Therapeutics $2.04 million 2,333.83 -$162.34 million ($3.99) -21.19
Q32 Bio $53.74 million 4.66 $29.82 million $3.34 2.50

Q32 Bio has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Dianthus Therapeutics and Q32 Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dianthus Therapeutics -7,436.50% -19.68% -18.95%
Q32 Bio N/A 17.03% 15.24%

Analyst Recommendations

This is a breakdown of recent ratings for Dianthus Therapeutics and Q32 Bio, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics 1 0 13 2 3.00
Q32 Bio 1 1 6 1 2.78

Dianthus Therapeutics presently has a consensus price target of $128.77, suggesting a potential upside of 52.30%. Q32 Bio has a consensus price target of $32.17, suggesting a potential upside of 284.54%. Given Q32 Bio’s higher probable upside, analysts clearly believe Q32 Bio is more favorable than Dianthus Therapeutics.

Volatility and Risk

Dianthus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Summary

Q32 Bio beats Dianthus Therapeutics on 9 of the 15 factors compared between the two stocks.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

About Q32 Bio

(Get Free Report)

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.